U.S. PHARMACOPEIA

Search USP29  
Multiple Electrolytes and Invert Sugar Injection Type 3
» Multiple Electrolytes and Invert Sugar Injection Type 3 is a sterile solution of a mixture of equal amounts of Dextrose and Fructose, or an equivalent solution produced by the hydrolysis of Sucrose, and suitable salts in Water for Injection to provide sodium, potassium, chloride, and ammonium ions. It contains not less than 90.0 percent and not more than 110.0 percent of the labeled amounts of sodium (Na), potassium (K), ammonium (NH4), and invert sugar (C6H12O6), and not less than 90.0 percent and not more than 120.0 percent of the labeled amount of chloride (Cl). It may contain Hydrochloric Acid or Sodium Hydroxide used to adjust the pH. It contains no antimicrobial agents.
Packaging and storage— Preserve in single-dose glass or plastic containers. Glass containers are preferably of Type I or Type II glass.
Labeling— The label states the content of each electrolyte in terms of milliequivalents in a given volume. The label states the total osmolar concentration in mOsmol per L. When the contents are less than 100 mL, the label alternatively may state the total osmolar concentration in mOsmol per mL.
Identification—
A: It responds to the Identification test under Invert Sugar Injection.
B: It responds to the flame tests for Sodium 191 and Potassium 191, and to the tests for Chloride 191 and Ammonium 191.
Pyrogen— It meets the requirements of the Pyrogen Test 151. [NOTE—Dilute, with Water for Injection, Injection containing more than 10% of invert sugar to give a concentration of 10% invert sugar.]
pH 791: between 3.0 and 5.5.
Completeness of inversion—
Mobile phase, Standard preparation, and Chromatographic system— Prepare as directed in the test for Completeness of inversion under Invert Sugar Injection.
Test preparation— Transfer an accurately measured volume of Injection, equivalent to about 2.5 g of invert sugar, to a 100-mL volumetric flask, dilute with water to volume, and mix.
Procedure— Proceed as directed for Procedure in the test for Completeness of inversion under Invert Sugar Injection. Calculate the quantity, in mg, of sucrose in the volume of Injection taken by the formula:
100C(rU / rS),
in which the terms are as defined therein. Not more than 1.5% of the quantity of invert sugar in the volume of Injection taken, based on the labeled amount, is found.
Residual solvents 467: meets the requirements.
(Official January 1, 2007)
Other requirements— It meets the requirements under Injections 1.
Assay for potassium and sodium—
Internal standard solution, Potassium stock solution, Sodium stock solution, Stock standard preparation, and Standard preparation— Prepare as directed in the Assay for potassium and sodium under Potassium Chloride in Sodium Chloride Injection.
Assay preparation— Transfer 5.0 mL of Injection to a 500-mL volumetric flask, dilute with Internal standard solution to volume, and mix.
Procedure— Proceed as directed for Procedure in the Assay for potassium and sodium under Potassium Chloride in Sodium Chloride Injection. Calculate the quantity, in mg, of potassium (K) in each mL of the Injection taken by the formula:
C(RU,766 / RU,671)(RS,671 / RS,766),
in which the terms are as defined therein. Each mg of potassium is equivalent to 0.02558 mEq of potassium. Calculate the quantity, in mg, of sodium (Na) in each mL of the Injection taken by the formula:
C(RU,589 / RU,671)(RS,671 / RS,589),
in which the terms are as defined therein. Each mg of sodium is equivalent to 0.04350 mEq of sodium.
Assay for chloride— Using the Injection, proceed as directed in the Assay for chloride under Multiple Electrolytes Injection Type 1.
Assay for ammonium— Using the Injection, proceed as directed in the Assay for ammonium under Multiple Electrolytes and Dextrose Injection Type 3.
Assay for invert sugar— Using the Injection, proceed as directed in the Assay for invert sugar under Multiple Electrolytes and Invert Sugar Injection Type 1.
Auxiliary Information— Staff Liaison : Daniel K. Bempong, Ph.D., Scientist
Expert Committee : (MDPS05) Monograph Development-Pulmonary and Steroids
USP29–NF24 Page 792
Phone Number : 1-301-816-8143